Product Description
Category: Anti obesity Drug, Gastrointestinal drugs
For the management of Obesity & Overweight
Product Data
Composition:
Each capsule contains orlistat120 mg.
Indications And Usage:
Slim-Safe® is indicated for:
- Obesity management, including weight loss, and weight maintenance, in conjunction with dietary modification.
- Reducing weight for obese diabetic subjects
Contraindications:
Orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis, and in patients with known hypersensitivity to the product.
Dosage & Administration:
120 mg capsule (one capsule) three times a day with each main meal containing fat (during or up to 1 hour after the meal). If a meal is occasionally missed or contains no fat, the dose of Slim-Safe® can be omitted. Doses above 120 mg three times a day have not been shown to provide additional benefit.
How Supplied:
Packs of one strip, each of 10 capsules.
Precautions:
- Patients should be advised to adhere to dietary guidelines. If orlistat is taken with a meal very high in fat, the possibility of gastrointestinal side effects increases.
- Patients should be counseled to take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition, because orlistat is shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. The supplement should be taken at least 2 hours before or after an orlistat dose or at bedtime.
- Caution should be exercised when prescribing orlistat to patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.
- Weight-loss induction by orlistat may be accompanied by improved metabolic control in diabetics, which might require a reduction in the dose of oral hypoglycemic medication (e.g., sulfonylureas, metformin) or insulin.
- Orlistat adds to the lipid-lowering effect of pravastatin.
Pharmacological Properties:
Orlistat exerts a reversible inhibitiory effect on gastric and pancreatic lipase in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat into absorbable free fatty acids and monoglycerides. The resulting caloric deficit has a positive effect on weight control. Systemic absorption of the drug is therefore not needed for its activity.
Pregnancy & Lactation:
Pregnancy: Category B. It is not known if orlistat is secreted in human milk. Therefore, it should not be taken by lactating women.
